Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Next Previous
X
Search
Trial Profile

An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cevaretigene ritoparvovec (Primary)
  • Indications Leber congenital amaurosis
  • Focus Adverse reactions
  • Acronyms OPTIRPE65
  • Sponsors MeiraGTx

    • Most Recent Events

    • 07 Nov 2019 According to a MeiraGTx media release, data from this trial were presented in September 2019 at the 52nd Annual Scientific meeting of the Retina Society and in October 2019 at American academy of ophthalmology Annual Meeting
    • 10 Sep 2019 According to a MeiraGTx media release, data from this trial will be presented by trial investigator, Michel Michaelides at 52nd Annual Scientific Meeting of The Retina Society and Retina Subspecialty Day of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting. The company will host a conference call and live webcast following Professor Michaelides presentation at AAO to review the data from trial.
    • 14 May 2019 Status changed from recruiting to completed according to a MeiraGTx media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top